Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 14/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 13/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 9/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 8/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3510680 | 0.99 | S1PR1 (0.50) | S1PR1S1PR3S1PR5S1PR4CES1 | |
| SCHEMBL385668 | 0.99 | S1PR1 (0.50) | S1PR1S1PR3S1PR5S1PR4CES1 | |
| SCHEMBL386336 | 0.96 | S1PR1 (0.53) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL387409 | 0.90 | S1PR1 (0.61) | S1PR1S1PR3S1PR5S1PR4S1PR2 | |
| SCHEMBL385611 | 0.90 | S1PR1 (0.52) | S1PR1S1PR3S1PR5S1PR4S1PR2 | |
| SCHEMBL386996 | 0.89 | S1PR1 (0.51) | S1PR1S1PR3S1PR5S1PR4POLB | |
| SCHEMBL386319 | 0.89 | S1PR1 (0.51) | S1PR1S1PR3S1PR5S1PR4S1PR2 | |
| SCHEMBL387393 | 0.89 | S1PR1 (0.51) | S1PR1S1PR3S1PR5S1PR4S1PR2 | |
| SCHEMBL385984 | 0.89 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL387334 | 0.89 | S1PR1 (0.51) | S1PR1S1PR3S1PR5S1PR4S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101650-B2 | Method for treating a immunology-related disease | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8067396-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20100035842-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20090326038-A1 | Method for treating a immunology-related disease | SANKYO COMPANY, LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7638551-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2009-12-29 | — | — | US | disclosed |
| EP-1471054-B1 | AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE | DAIICHI SANKYO CO LTD (JP) | 2009-07-01 | — | — | EP | disclosed |
| US-20070142335-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070105933-A1 | Amino alcohol compounds | SANKYO COMPANY, LIMITED (JP) | 2007-05-10 | — | — | US | disclosed |
| US-7199150-B2 | Amino alcohol compounds | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20050043386-A1 | Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these | SANKYO COMPANY, LIMITED (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1471054-A1 | AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE | Sankyo Company, Limited (JP) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043386-A1 | Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these | PHOSPHO1, CD4, FCGRT | S1PR1 257/4885S1PR3 414/4885S1PR5 503/4885 |
| US-20090326038-A1 | Method for treating a immunology-related disease | C3AR1, HRH3, HRH2 | S1PR1 159/4885S1PR3 194/4885S1PR5 345/4885 |
| US-20070105933-A1 | Amino alcohol compounds | ADH1C, C9, SSB | S1PR1 465/4885S1PR3 504/4885S1PR5 1007/4885 |
| US-20070142335-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | HRH3, C3AR1, HRH4 | S1PR1 70/4885S1PR3 89/4885S1PR5 163/4885 |
| US-20100035842-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | PHOSPHO1, ADH1C, ADH1A | S1PR1 593/4885S1PR3 622/4885S1PR5 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.